** Shares of Imagion Biosystems IBX.AX rise as much as 52.9% to A$0.026, their highest since February 27

** Stock logs the largest intraday pct jump since early September 2025

** Medical imaging firm receives notice from the U.S. Food and Drug Administration for clearing the Investigational New Drug (IND) application for co's MagSense HER2 imaging agent

** MagSense technology is a class of MRI imaging agents that improves cancer detection

** Says FDA's allowance to proceed with the Phase 1b/2 clinical study in HER2+ breast cancer patients indicates that co comprehensively addressed all necessary logistical, analytical, quality and safety prerequisites

** More than 42.3 million shares change hands, 19.2 times the 30-day average

** Stock down 20% YTD, including the day's moves